Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination With Gemcitabine and in Combination With Chemoradiation (Capecitabine and Radiation) in Patients With Completely-Resected Pancreatic Carcinoma.

Trial Profile

An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination With Gemcitabine and in Combination With Chemoradiation (Capecitabine and Radiation) in Patients With Completely-Resected Pancreatic Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Capecitabine; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2010 Results have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top